Israel Englander’s Ovid Therapeutics OVID Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $86.9K | Sell |
32,295
-1,464,223
| -98% | -$3.78M | ﹤0.01% | 5528 |
|
|
2026
Q1 | $3.32M | Buy |
1,496,518
+157,053
| +12% | +$281K | ﹤0.01% | 3377 |
|
|
2025
Q4 | $2.18M | Buy |
1,339,465
+353,172
| +36% | +$544K | ﹤0.01% | 3862 |
|
|
2025
Q3 | $1.28M | Sell |
986,293
-66,041
| -6% | -$57.2K | ﹤0.01% | 4420 |
|
|
2025
Q2 | $347K | Buy |
+1,052,334
| New | +$317K | ﹤0.01% | 5121 |
|
|
2024
Q3 | – | Sell |
-78,024
| Closed | -$60K | – | 6375 |
|
|
2024
Q2 | $60K | Sell |
78,024
-67,941
| -47% | -$189K | ﹤0.01% | 5394 |
|
|
2024
Q1 | $445K | Buy |
+145,965
| New | +$488K | ﹤0.01% | 4891 |
|
|
2023
Q2 | – | Sell |
-272,916
| Closed | -$704K | – | 6535 |
|
|
2023
Q1 | $704K | Buy |
272,916
+131,212
| +93% | +$311K | ﹤0.01% | 4381 |
|
|
2022
Q4 | $264K | Sell |
141,704
-88,460
| -38% | -$151K | ﹤0.01% | 5175 |
|
|
2022
Q3 | $424K | Sell |
230,164
-14,046
| -6% | -$29.4K | ﹤0.01% | 5102 |
|
|
2022
Q2 | $525K | Sell |
244,210
-207,856
| -46% | -$502K | ﹤0.01% | 4913 |
|
|
2022
Q1 | $1.42M | Buy |
452,066
+66,299
| +17% | +$209K | ﹤0.01% | 4181 |
|
|
2021
Q4 | $1.24M | Sell |
385,767
-27,124
| -7% | -$92.9K | ﹤0.01% | 4205 |
|
|
2021
Q3 | $1.39M | Sell |
412,891
-352,759
| -46% | -$1.29M | ﹤0.01% | 4324 |
|
|
2021
Q2 | $2.99M | Buy |
+765,650
| New | +$3.02M | ﹤0.01% | 3439 |
|
|
2021
Q1 | – | Sell |
-254,046
| Closed | -$587K | – | 6364 |
|
|
2020
Q4 | $587K | Buy |
254,046
+217,739
| +600% | +$1.01M | ﹤0.01% | 4077 |
|
|
2020
Q3 | $208 | Sell |
36,307
-486,289
| -93% | -$3.25M | ﹤0.01% | 4045 |
|
|
2020
Q2 | $3.85M | Buy |
522,596
+123,638
| +31% | +$578K | 0.01% | 1995 |
|
|
2020
Q1 | $1.19M | Buy |
398,958
+79,121
| +25% | +$267K | ﹤0.01% | 2359 |
|
|
2019
Q4 | $1.33M | Buy |
319,837
+218,876
| +217% | +$691K | ﹤0.01% | 2857 |
|
|
2019
Q3 | $327K | Sell |
100,961
-247,014
| -71% | -$561K | ﹤0.01% | 3514 |
|
|
2019
Q2 | $644K | Buy |
+347,975
| New | +$621K | ﹤0.01% | 3066 |
|
|
2019
Q1 | – | Sell |
-22,286
| Closed | -$54K | – | 4238 |
|
|
2018
Q4 | $54K | Sell |
22,286
-68,947
| -76% | -$315K | ﹤0.01% | 3609 |
|
|
2018
Q3 | $517K | Buy |
91,233
+76,153
| +505% | +$577K | ﹤0.01% | 3241 |
|
|
2018
Q2 | $118K | Sell |
15,080
-44,264
| -75% | -$380K | ﹤0.01% | 3630 |
|
|
2018
Q1 | $420K | Buy |
+59,344
| New | +$480K | ﹤0.01% | 3079 |
|
|
2017
Q3 | – | Sell |
-18,443
| Closed | -$193K | – | 3769 |
|
|
2017
Q2 | $193K | Buy |
+18,443
| New | +$241K | ﹤0.01% | 3205 |
|
Other funds holding OVID
JT
EAM
RCM
AAA
ACM
Israel Englander's OVID Position: Q2 2026 in Review
Israel Englander reduced its Ovid Therapeutics (OVID) stake by 98% in Q2 2026, selling an estimated $3.78M and leaving 32,295 shares worth $86.9K. The position accounts for ﹤0.01% of the portfolio, ranked #5528.
Israel Englander first reported a position in OVID in Q2 2017 and has held it in 27 quarters since. The position peaked at $3.85M in Q2 2020. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.
- Israel Englander held 32,295 shares of Ovid Therapeutics worth $86.9K as of Q2 2026.
- Israel Englander sold 1,464,223 Ovid Therapeutics shares in Q2 2026, an estimated $3.78M.
- Ovid Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #5528 holding.
- Israel Englander first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 27 quarters since.
- Israel Englander's Ovid Therapeutics position peaked at $3.85M in Q2 2020.
- 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.